[go: up one dir, main page]

DK2968369T3 - Neuroaktive steroider og fremgangsmåder til anvendelse deraf - Google Patents

Neuroaktive steroider og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2968369T3
DK2968369T3 DK14774060.9T DK14774060T DK2968369T3 DK 2968369 T3 DK2968369 T3 DK 2968369T3 DK 14774060 T DK14774060 T DK 14774060T DK 2968369 T3 DK2968369 T3 DK 2968369T3
Authority
DK
Denmark
Prior art keywords
substituted
unsubstituted
compound
group
hydrogen
Prior art date
Application number
DK14774060.9T
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Boyd L Harrison
Albert J Robichaud
Francesco G Salituro
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Application granted granted Critical
Publication of DK2968369T3 publication Critical patent/DK2968369T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (19)

1. Forbindelse med formel fh:
eller et farmaceutisk acceptabelt salt deraf; hvor: R1 er en substitueret eller usubstitueret alifatisk forbindelse; R2 er hydrogen, halogen, substitueret eller usubstitueret Ci-6alkyl, substitueret eller usubstitueret cyclopropyl eller -ORA2, hvor RA2 er hydrogen eller substitueret eller usubstitueret alkyl; R3a er hydrogen eller -ORA3, hvor RA3 er hydrogen eller substitueret eller usubstitueret alkyl, og R3b er hydrogen; eller R3a og R3b er forbundet til frembringelse af en oxo(=0)-gruppe; R4 er hydrogen, substitueret eller usubstitueret alkyl eller halogen; X er -C(Rx)2- eller -O-, hvor Rx er hydrogen eller fluor, eller én Rx-gruppe og R5b er forbundet til frembringelse af en dobbeltbinding; hvert tilfælde af R5a og R5b uafhængigt er hydrogen eller fluor; R6a er en ikke-hydrogengruppe valgt fra gruppen, der består af en substitueret og usubstitueret alkyl-, substitueret og usubstitueret alkenyl-, substitueret og usubstitueret alkynyl-, substitueret og usubstitueret carbocyclyl-, substitueret og usubstitueret heterocyclyl-, substitueret og usubstitueret aryl- og substitueret og usubstitueret heteroarylgruppe, hvor ikke-hydrogengruppen eventuelt er substitueret med fluor; og R6b er hydrogen eller en substitueret eller usubstitueret alkylgruppe, der eventuelt er substitueret med fluor; .....er en enkelt- eller dobbeltbinding, forudsat at hvis der er en enkeltbinding til stede, så er hydrogenet i C5 i alfa-konfigurationen; forudsat at: (1) mindst én af Rx, R5a og R5b er fluor; eller (2) mindst én af R6a og R6b er en ikke-hydrogengruppe, der er substitueret med en fluor; eller (3) R6a er en ikke-hydrogengruppe, der omfatter mellem to og ti carbonatomer; og yderligere forudsat at forbindelsen ikke er:
2. Forbindelse ifølge krav 1, hvor R1 er usubstitueret Ci-3alkyl; for eksempel -CH3, -CH2CH3 eller -CH2CH2CH3.
3. Forbindelse ifølge krav 1, hvor R2 er hydrogen.
4. Forbindelse ifølge krav 1, hvor R3a og R3b begge er hydrogen.
5. Forbindelse ifølge krav 1, hvor R4 er hydrogen.
6. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen, der består af:
eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
9. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
11. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
13. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
14. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
15. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
16. Forbindelse ifølge krav 1, hvor forbindelsen er:
eller et farmaceutisk acceptabelt salt deraf.
17. Farmaceutisk sammensætning, der omfatter en forbindelse eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af ovennævnte krav og et farmaceutisk acceptabelt bæremateriale.
18. Forbindelse eller farmaceutisk acceptabelt salt deraf eller farmaceutisk sammensætning dermed ifølge et hvilket som helst af ovennævnte krav til anvendelse til behandling eller forebyggelse af en CNS-relateret tilstand; for eksempel hvor den CNS-relaterede tilstand er en angstforstyrrelse (herunder OCD, posttraumatisk stress og social fobi), Alzheimers sygdom og andre former for demens, en humørforstyrrelse (herunder depression, bipolar lidelse og dystymisk forstyrrelse), skizofreni eller anden psykotisk forstyrrelse (herunder skizoaffektiv forstyrrelse), en søvnforstyrrelse (herunder insomni), en personlighedsforstyrrelse, en autismespektrumforstyrrelse, Retts syndrom, smerter, krampeanfald, apopleksi, traumatisk hjerneskade, Huntingtons sygdom, Parkinsons sygdom eller tinnitus.
19. Forbindelse eller farmaceutisk acceptabelt salt deraf eller farmaceutisk sammensætning dermed ifølge et hvilket som helst af kravene 1-16 til anvendelse til behandling eller forebyggelse af hjerne-ekscitabilitet hos et individ, der er modtagelig for eller lider af en tilstand, der er forbundet med hjerne-ekscitabilitet.
DK14774060.9T 2013-03-13 2014-03-13 Neuroaktive steroider og fremgangsmåder til anvendelse deraf DK2968369T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779735P 2013-03-13 2013-03-13
PCT/US2014/026784 WO2014160480A1 (en) 2013-03-13 2014-03-13 Neuroactive steroids and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2968369T3 true DK2968369T3 (da) 2018-12-17

Family

ID=51625437

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18190034.1T DK3461834T3 (da) 2013-03-13 2014-03-13 Neuroaktive steroider
DK14774060.9T DK2968369T3 (da) 2013-03-13 2014-03-13 Neuroaktive steroider og fremgangsmåder til anvendelse deraf
DK21172859.7T DK3932932T3 (da) 2013-03-13 2014-03-13 Neuroaktive sterioder og fremgangsmåder til anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18190034.1T DK3461834T3 (da) 2013-03-13 2014-03-13 Neuroaktive steroider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21172859.7T DK3932932T3 (da) 2013-03-13 2014-03-13 Neuroaktive sterioder og fremgangsmåder til anvendelse deraf

Country Status (25)

Country Link
US (6) US20160031930A1 (da)
EP (4) EP3932932B8 (da)
JP (6) JP6255082B2 (da)
CN (3) CN112375115A (da)
AU (5) AU2014243773B2 (da)
BR (1) BR112015022174B1 (da)
CA (2) CA3114062A1 (da)
CY (2) CY1120934T1 (da)
DK (3) DK3461834T3 (da)
ES (3) ES3042115T3 (da)
FI (1) FI3932932T3 (da)
HR (2) HRP20181994T1 (da)
HU (1) HUE055668T2 (da)
IL (3) IL318314A (da)
LT (3) LT2968369T (da)
MX (2) MX362544B (da)
PL (3) PL2968369T3 (da)
PT (3) PT2968369T (da)
RS (3) RS58166B1 (da)
RU (1) RU2684103C2 (da)
SI (3) SI2968369T1 (da)
SM (3) SMT202500336T1 (da)
TR (1) TR201817995T4 (da)
WO (1) WO2014160480A1 (da)
ZA (1) ZA201506729B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
EP2633621B1 (en) 2010-10-27 2017-08-30 Merus Audio ApS Audio amplifier using multi-level pulse width modulation
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
RU2684103C2 (ru) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Нейроактивные стероиды и способы их применения
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) * 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
IL292465B2 (en) 2014-10-07 2025-06-01 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
WO2017007832A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP4609866A3 (en) * 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2018530585A (ja) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
RU2754130C2 (ru) * 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
MA46351A (fr) * 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
JP7118957B2 (ja) * 2016-10-18 2022-08-16 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
TWI836485B (zh) * 2016-10-18 2024-03-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
CN106632565A (zh) * 2016-11-07 2017-05-10 湖南科瑞生物制药股份有限公司 一种合成胆固醇的新方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN119950517A (zh) 2019-12-06 2025-05-09 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
EP4333856A1 (en) * 2021-05-04 2024-03-13 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
EP4351588A1 (en) 2021-06-11 2024-04-17 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
US20240368214A1 (en) * 2021-08-25 2024-11-07 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
JP2024534558A (ja) * 2021-09-22 2024-09-20 セージ セラピューティクス， インコーポレイテッド 重水素化ｎｍｄａ正調節化合物及びその使用方法
EP4430056A1 (en) * 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023114152A1 (en) * 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of huntington's disease
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CN114478672B (zh) * 2022-01-27 2024-06-14 浙江仙居君业药业有限公司 一种he3286的合成方法
AU2023287695A1 (en) 2022-06-24 2025-02-06 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
JP2025523826A (ja) 2022-07-12 2025-07-25 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイドの結晶形態
TW202508603A (zh) 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025227053A1 (en) * 2024-04-25 2025-10-30 Sage Therapeutics, Inc. Nmda receptor positive allosteric modulatory compositions and methods of use thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (da) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
DE3664909D1 (en) 1985-05-30 1989-09-14 Taisho Pharmaceutical Co Ltd Vitamin d3 derivatives
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU691905B2 (en) * 1994-02-14 1998-05-28 Purdue Pharma Ltd. Androstanes and pregnanes for allosteric modulation of GABA receptor
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
EP0808325B1 (en) 1994-11-23 2001-01-17 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
US5925630A (en) * 1995-06-06 1999-07-20 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
WO1997000884A1 (en) 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
CA2331299A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
AU3701199A (en) 1998-05-13 1999-11-29 Novo Nordisk A/S Meiosis regulating compounds
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
ES2296928T3 (es) * 2001-05-03 2008-05-01 The University Of Chicago Receptores x hepaticos.
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
JP2005511713A (ja) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
KR20100093621A (ko) 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
CA2585471A1 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) * 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
DK2711371T3 (da) 2006-11-21 2018-04-16 Asarina Pharma Ab Anvendelse af pregnan- og androstansteroider til fremstilling af en farmaceutisk sammensætning til behandling af CNS-forstyrrelser
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
US20110118353A1 (en) 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
KR101325374B1 (ko) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
SG195568A1 (en) 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP2542085A4 (en) * 2010-03-03 2013-12-04 Satori Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
CN103842356B (zh) 2011-10-07 2017-03-15 武田药品工业株式会社 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
HUE039057T2 (hu) 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
CN105073119A (zh) 2013-01-23 2015-11-18 司菲埃拉制药私人有限公司 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
RU2684103C2 (ru) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Нейроактивные стероиды и способы их применения
CN119269811A (zh) 2013-03-13 2025-01-07 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
ES2998982T3 (en) 2013-04-17 2025-02-24 Sage Therapeutics Inc 19-nor neuroactive steroids for inducing sedation
CN112826930A (zh) 2014-02-08 2021-05-25 豪夫迈·罗氏有限公司 治疗阿尔茨海默氏病的方法
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
IL292465B2 (en) 2014-10-07 2025-06-01 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP4609866A3 (en) 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
RU2754130C2 (ru) 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
NZ790186A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
TWI836485B (zh) 2016-10-18 2024-03-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
JP7118957B2 (ja) 2016-10-18 2022-08-16 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
WO2018237350A1 (en) 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
US20190160078A1 (en) 2017-11-10 2019-05-30 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders

Also Published As

Publication number Publication date
RS67266B1 (sr) 2025-10-31
US20170305960A1 (en) 2017-10-26
CN105246486B (zh) 2020-11-03
HRP20211300T1 (hr) 2021-11-12
EP3932932A1 (en) 2022-01-05
PT2968369T (pt) 2018-12-05
CN118702755A (zh) 2024-09-27
LT2968369T (lt) 2018-12-27
JP2016513663A (ja) 2016-05-16
ES2886506T3 (es) 2021-12-20
SMT201800657T1 (it) 2019-01-11
NZ712141A (en) 2020-10-30
LT3461834T (lt) 2021-10-25
PT3461834T (pt) 2021-09-10
AU2021200205B2 (en) 2022-09-01
JP2025120299A (ja) 2025-08-15
FI3932932T3 (fi) 2025-10-15
US11104701B2 (en) 2021-08-31
US20160031930A1 (en) 2016-02-04
DK3932932T3 (da) 2025-08-18
CN105246486A (zh) 2016-01-13
HK1220375A1 (en) 2017-05-05
CY1124629T1 (el) 2022-07-22
EP2968369A1 (en) 2016-01-20
MX2015012430A (es) 2016-02-03
PL3461834T3 (pl) 2021-12-27
US11905309B2 (en) 2024-02-20
HUE055668T2 (hu) 2021-12-28
HRP20181994T1 (hr) 2019-03-08
JP6530804B2 (ja) 2019-06-12
SI2968369T1 (sl) 2019-01-31
PL2968369T3 (pl) 2019-03-29
CA3114062A1 (en) 2014-10-02
JP2019135261A (ja) 2019-08-15
BR112015022174A8 (pt) 2019-11-26
JP2022180606A (ja) 2022-12-06
JP6255082B2 (ja) 2017-12-27
JP2021152086A (ja) 2021-09-30
AU2022279366B2 (en) 2025-02-06
NZ751196A (en) 2020-10-30
IL318314A (en) 2025-03-01
CY1120934T1 (el) 2019-12-11
EP2968369B1 (en) 2018-08-29
US10227375B2 (en) 2019-03-12
US20190127414A1 (en) 2019-05-02
AU2021200205A1 (en) 2021-03-18
EP3461834B1 (en) 2021-05-19
AU2019201275B2 (en) 2020-10-15
JP7317898B2 (ja) 2023-07-31
EP3932932B8 (en) 2025-11-19
EP4643945A2 (en) 2025-11-05
AU2022279366A1 (en) 2023-01-19
AU2014243773B2 (en) 2018-12-13
IL280068B1 (en) 2025-02-01
SI3932932T1 (sl) 2025-10-30
MX388210B (es) 2025-03-19
RU2015143466A (ru) 2017-04-18
RU2684103C2 (ru) 2019-04-04
JP7715692B2 (ja) 2025-07-30
RS58166B1 (sr) 2019-03-29
EP2968369A4 (en) 2016-09-14
SMT202500336T1 (it) 2025-11-10
WO2014160480A1 (en) 2014-10-02
DK3461834T3 (da) 2021-08-23
RS62235B1 (sr) 2021-09-30
EP3461834A1 (en) 2019-04-03
BR112015022174A2 (pt) 2017-07-18
SMT202100475T1 (it) 2021-09-14
US20180237470A1 (en) 2018-08-23
SI3461834T1 (sl) 2021-11-30
US20220064207A1 (en) 2022-03-03
ES3042115T3 (en) 2025-11-18
IL280068A (en) 2021-03-01
RU2019109033A (ru) 2019-05-21
CN112375115A (zh) 2021-02-19
JP2018030890A (ja) 2018-03-01
US20240287125A1 (en) 2024-08-29
ZA201506729B (en) 2017-09-27
TR201817995T4 (en) 2019-02-21
CA2905359C (en) 2021-05-25
EP3932932B1 (en) 2025-07-16
ES2699445T3 (es) 2019-02-11
PL3932932T3 (pl) 2025-11-24
MX362544B (es) 2019-01-24
AU2014243773A1 (en) 2015-10-01
LT3932932T (lt) 2025-09-10
CA2905359A1 (en) 2014-10-02
IL241301A0 (en) 2015-11-30
PT3932932T (pt) 2025-09-29
IL241301B (en) 2021-01-31
AU2025203021A1 (en) 2025-05-22
AU2019201275A1 (en) 2019-03-14
WO2014160480A8 (en) 2015-01-08
BR112015022174B1 (pt) 2022-07-05
IL280068B2 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
DK2968369T3 (da) Neuroaktive steroider og fremgangsmåder til anvendelse deraf
HK40066987A (en) Neuroactive steriods and methods of use thereof
HK40007016A (en) Neuroactive steroids
HK40007016B (en) Neuroactive steroids
RU2808166C2 (ru) Нейроактивные стероиды и способы их применения
HK1220375B (en) Neuroactive steroids and methods of use thereof